se ha leído el artículo
array:24 [ "pii" => "S1578219018303172" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.06.024" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2019" "copyright" => "Elsevier España, S.L.U. and AEDV" "copyrightAnyo" => "2018" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:765-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2 "HTML" => 2 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731018303363" "issn" => "00017310" "doi" => "10.1016/j.ad.2018.06.008" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2019" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:765-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 165 "formatos" => array:2 [ "HTML" => 97 "PDF" => 68 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Comentarios Editoriales</span>" "titulo" => "Vismodegib, una experiencia local" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "765" "paginaFinal" => "766" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Local Experience with Vismodegib" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Pasquali" "autores" => array:1 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Pasquali" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219018303172" "doi" => "10.1016/j.adengl.2018.06.024" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303172?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018303363?idApp=UINPBA000044" "url" => "/00017310/0000010900000009/v1_201811020614/S0001731018303363/v1_201811020614/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S1578219018303524" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.10.001" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2051" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:766" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2 "formatos" => array:2 [ "EPUB" => 1 "HTML" => 1 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "An Algorithm to Guide the Rational, Evidence-Based Use of Omalizumab in the Treatment of Chronic Urticaria" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "766" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Aproximación a un uso racional y reglado de omalizumab en la urticaria crónica" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Ruiz-Villaverde" "autores" => array:1 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Ruiz-Villaverde" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018303983" "doi" => "10.1016/j.ad.2018.08.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018303983?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303524?idApp=UINPBA000044" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303524/v1_201811020640/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S1578219018303214" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.07.025" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2028" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:765" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2 "formatos" => array:2 [ "EPUB" => 1 "HTML" => 1 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentary</span>" "titulo" => "Coding of Dermatologic Diagnoses: An Unresolved Issue" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "765" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "La codificación de diagnósticos dermatológicos. Una cuestión aún por resolver" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "I. Belinchón Romero" "autores" => array:1 [ 0 => array:2 [ "nombre" => "I." "apellidos" => "Belinchón Romero" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018303478" "doi" => "10.1016/j.ad.2018.07.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018303478?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303214?idApp=UINPBA000044" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303214/v1_201811020640/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "Local Experience with Vismodegib" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "765" "paginaFinal" => "766" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "P. Pasquali" "autores" => array:1 [ 0 => array:3 [ "nombre" => "P." "apellidos" => "Pasquali" "email" => array:1 [ 0 => "pasqualipaola@gmail.com" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Departamento de Dermatología, Pius Hospital de Valls, Cambrils, Tarragona, España" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Vismodegib, una experiencia local" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Vismodegib is the first medication to be approved by the United States Food and Drug Administration and the European Medicines Agency for the treatment of locally advanced basal cell carcinoma in patients who are not candidates for surgery or radiotherapy and for the treatment of metastatic basal cell carcinoma. Therefore, this Hedgehog pathway inhibitor has generated high hopes among oncologists and dermatologists, since no alternative treatment is available for these patients, whose condition is difficult to manage and for whom no standard therapeutic approach has been established.</p><p id="par0010" class="elsevierStylePara elsevierViewall">Initial enthusiasm has been tempered by the emergence of resistance, adverse effects that are sometimes poorly tolerated, possible liver toxicity, and a questionable increased risk of developing squamous cell carcinoma. However, experience with vismodegib as a neoadjuvant approach before surgery is growing. Similarly, we now know more about pulse dosing to diminish adverse effects and combination with other Hedgehog pathway inhibitors to increase effectiveness. Knowledge of the response to this drug in the patients we treat, therefore, is now particularly valuable; hence, the importance of the publication by Bernia et al.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> in this issue of <span class="elsevierStyleSmallCaps">Actas Dermosifiliográficas.</span></p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Pasquali P. Local Experience with Vismodegib. Actas Dermosifiliogr. 2018;109:765–766.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Reference" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:1 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Experiencia con Vismodegib en Carcinoma Basocelular avanzado en un centro oncológico" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Bernia" 1 => "B. Llombart" 2 => "C. Serra" 3 => "B. Bancalari" 4 => "E. Nagore" 5 => "C. Requena" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2018" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303172/v1_201811020640/en/main.assets" "Apartado" => array:4 [ "identificador" => "66476" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Commentaries" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010900000009/v1_201811020640/S1578219018303172/v1_201811020640/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303172?idApp=UINPBA000044" ]
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 9 | 8 | 17 |
2024 Octubre | 69 | 32 | 101 |
2024 Septiembre | 53 | 24 | 77 |
2024 Agosto | 74 | 60 | 134 |
2024 Julio | 61 | 26 | 87 |
2024 Junio | 66 | 34 | 100 |
2024 Mayo | 49 | 23 | 72 |
2024 Abril | 62 | 35 | 97 |
2024 Marzo | 47 | 26 | 73 |
2024 Febrero | 36 | 28 | 64 |
2024 Enero | 33 | 34 | 67 |
2023 Diciembre | 43 | 10 | 53 |
2023 Noviembre | 47 | 24 | 71 |
2023 Octubre | 42 | 19 | 61 |
2023 Septiembre | 32 | 31 | 63 |
2023 Agosto | 26 | 15 | 41 |
2023 Julio | 33 | 31 | 64 |
2023 Junio | 36 | 23 | 59 |
2023 Mayo | 40 | 23 | 63 |
2023 Abril | 36 | 20 | 56 |
2023 Marzo | 38 | 17 | 55 |
2023 Febrero | 31 | 23 | 54 |
2023 Enero | 44 | 31 | 75 |
2022 Diciembre | 29 | 39 | 68 |
2022 Noviembre | 20 | 25 | 45 |
2022 Octubre | 27 | 14 | 41 |
2022 Septiembre | 22 | 27 | 49 |
2022 Agosto | 24 | 33 | 57 |
2022 Julio | 21 | 42 | 63 |
2022 Junio | 21 | 38 | 59 |
2022 Mayo | 30 | 35 | 65 |
2022 Abril | 38 | 37 | 75 |
2022 Marzo | 49 | 37 | 86 |
2022 Febrero | 35 | 29 | 64 |
2022 Enero | 33 | 32 | 65 |
2021 Diciembre | 32 | 50 | 82 |
2021 Noviembre | 41 | 47 | 88 |
2021 Octubre | 38 | 54 | 92 |
2021 Septiembre | 30 | 38 | 68 |
2021 Agosto | 31 | 35 | 66 |
2021 Julio | 28 | 35 | 63 |
2021 Junio | 23 | 32 | 55 |
2021 Mayo | 35 | 50 | 85 |
2021 Abril | 82 | 67 | 149 |
2021 Marzo | 51 | 38 | 89 |
2021 Febrero | 43 | 38 | 81 |
2021 Enero | 33 | 41 | 74 |
2020 Diciembre | 41 | 35 | 76 |
2020 Noviembre | 34 | 41 | 75 |
2020 Octubre | 30 | 20 | 50 |
2020 Septiembre | 40 | 22 | 62 |
2020 Agosto | 21 | 28 | 49 |
2020 Julio | 15 | 25 | 40 |
2020 Junio | 31 | 33 | 64 |
2020 Mayo | 21 | 12 | 33 |
2020 Abril | 16 | 13 | 29 |
2020 Marzo | 19 | 10 | 29 |
2020 Febrero | 1 | 0 | 1 |
2019 Abril | 1 | 0 | 1 |
2018 Noviembre | 1 | 0 | 1 |